Preventing SARS-CoV-2 infection by blocking a tissue serine protease.
COVID-19
COVID-19 drug treatment
Serine proteases
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Journal
Therapeutic advances in infectious disease
ISSN: 2049-9361
Titre abrégé: Ther Adv Infect Dis
Pays: England
ID NLM: 101606715
Informations de publication
Date de publication:
Historique:
received:
10
04
2020
accepted:
19
05
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
25
6
2020
Statut:
epublish
Résumé
Currently, there are no proven pharmacologic interventions to reduce the clinical impact and prevent complications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, the cause of the ongoing Coronavirus Disease of 2019 (COVID-19) pandemic. Selecting specific pharmacological targets for the treatment of viral pathogens has traditionally relied in blockage of specific steps in their replicative lifecycle in human cells. However, an alternative approach is reducing the molecular cleavage of the viral surface spike protein of SARS-CoV-2 to prevent viral entry into epithelial cells.
Identifiants
pubmed: 32577236
doi: 10.1177/2049936120933076
pii: 10.1177_2049936120933076
pmc: PMC7288835
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2049936120933076Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
J Mol Genet Med. 2008 Nov 29;3(1):167-75
pubmed: 19565019
Ann Acad Med Singapore. 2020 Jan;49(3):108-118
pubmed: 32200400
Trials. 2019 Aug 14;20(1):501
pubmed: 31412955
Lancet Infect Dis. 2014 Jan;14(1):57-69
pubmed: 24239327
J Pathol. 2015 Jan;235(2):185-95
pubmed: 25270030
Trends Microbiol. 1994 Feb;2(2):39-43
pubmed: 8162439
Chest. 2013 Jul;144(1):200-207
pubmed: 23412700
J Virol. 1994 Sep;68(9):6074-8
pubmed: 8057485
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651